166 related articles for article (PubMed ID: 32873264)
21. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim SH; Chung YH; Yang SH; Kim JA; Jang MK; Kim SE; Lee D; Lee SH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Suh DJ
Korean J Hepatol; 2009 Sep; 15(3):320-30. PubMed ID: 19783881
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and Prognostic Performance of Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin for Gastrointestinal Cancers.
Jiang L; Hochwald S; Deng S; Chen Y; Tan C; Zhong Q; Huang H
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775874
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer.
Schneider S; Yochim J; Brabender J; Uchida K; Danenberg KD; Metzger R; Schneider PM; Salonga D; Hölscher AH; Danenberg PV
Clin Cancer Res; 2004 Mar; 10(5):1588-96. PubMed ID: 15014008
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
Ray P; Quantin X; Grenìer J; Pujol JL
Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
[TBL] [Abstract][Full Text] [Related]
25. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
[TBL] [Abstract][Full Text] [Related]
26. Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy.
Byeon H; Lee SD; Hong EK; Lee DE; Kim BH; Seo Y; Joo J; Han SS; Kim SH; Park SJ
Pathol Res Pract; 2018 Jun; 214(6):814-820. PubMed ID: 29753515
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.
Carvalho S; Troost EG; Bons J; Menheere P; Lambin P; Oberije C
Radiother Oncol; 2016 Jun; 119(3):487-94. PubMed ID: 27139126
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma.
Xie H; Song J; Du R; Liu K; Wang J; Tang H; Bai F; Liang J; Lin T; Liu J; Fan D
Dig Liver Dis; 2007 Feb; 39(2):167-72. PubMed ID: 17161983
[TBL] [Abstract][Full Text] [Related]
31. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.
Zhou C; Zhou HJ; Zhang XF; Lou LL; Ye QH; Zheng Y; Wang J; Zhu HT; Dong QZ; Jia HL; Zhu WW; Guo L; Zhao Y; Gao DM; Qin LX
Ann Surg Oncol; 2013 Mar; 20(3):929-37. PubMed ID: 23203407
[TBL] [Abstract][Full Text] [Related]
32. Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.
Elbaiomy MA; Akl T; Elhelaly R; El-Beshbishi W; El Ghonemy MS; Elzehery R
Curr Oncol; 2020 Oct; 27(5):e444-e450. PubMed ID: 33173383
[TBL] [Abstract][Full Text] [Related]
33. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
[TBL] [Abstract][Full Text] [Related]
34. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of osteopontin expression in cervical cancer.
Cho H; Hong SW; Oh YJ; Kim MA; Kang ES; Lee JM; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
J Cancer Res Clin Oncol; 2008 Aug; 134(8):909-17. PubMed ID: 18210151
[TBL] [Abstract][Full Text] [Related]
36. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population.
Joseph S; Harrington R; Walter D; Goldberg JD; Li X; Beck A; Litton T; Hirsch N; Blasberg J; Slomiany M; Rom W; Pass H; Donington J
Cancer Biomark; 2012; 12(4):177-84. PubMed ID: 23568008
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of serum soluble DR5 levels in small-cell lung cancer.
Wan Z; Zhang X; Yu X; Hou Y
Int J Med Sci; 2019; 16(3):403-408. PubMed ID: 30911274
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
39. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
